[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"molecular-imaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:molecular-imaging":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,69,89,120,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100633795","delayed-psma-petct-imaging-for-diagnosing-clinically-significant-prostate-cancer-in-biopsy-nave-men-with-suspected-prostate-cancer-100633795",false,"NCT07531329","Delayed PSMA PET\u002FCT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer","DEPICT","Inclusion Criteria:\n\n1. Patients with suspected prostate cancer and a PSA level ≥4.0 ng\u002FmL\n2. Patients who undergo PSMA PET imaging (including delayed phase imaging) prior to prostate biopsy\n3. Patients who are willing to undergo prostate biopsy\n4. Patients who provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Patients who have received any prior prostate cancer-related treatment before the initial PSMA PET scan\n2. Patients with a history of other malignancies within the past two years\n3. Patients judged by the study investigator to be at risk for serious complications that could interfere with the normal conduct of the study","MALE","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Brief Summary This prospective, multicenter study evaluates whether delayed PSMA PET imaging improves diagnostic efficacy for detecting clinically significant prostate cancer (Gleason score ≥7) compared with standard imaging in patients with suspected newly diagnosed prostate cancer. Each patient serves as their own control, with diagnostic performance compared between standard (60-minute) and delayed (2-3 hour) acquisitions.\n\nBackground PSMA PET has transformed prostate cancer imaging, with emerging evidence suggesting delayed acquisition may further improve diagnostic accuracy by increasing tumor-to-background ratio. Recent studies demonstrate that delayed imaging significantly reduces equivocal findings and enhances detection of clinically significant prostate cancer.\n\nNeed While standard PSMA PET is well-validated, prospective multicenter data specifically evaluating the incremental diagnostic value of delayed imaging for clinically significant prostate cancer in treatment-naïve patients are lacking. This study addresses this gap by systematically comparing standard and delayed imaging in a large, well-defined cohort.\n\nPrimary Outcome The primary outcome is to compare the area under the curve (AUC) of delayed SUVmax versus standard SUVmax for detecting clinically significant prostate cancer (csPCa), and to determine whether delayed imaging is superior to standard imaging.\n\nSecondary Outcomes\n\n1. Optimal diagnostic thresholds for delayed imaging\n\n   1. Determine the optimal threshold for delayed SUVmax using ROC analysis with the Youden index;\n   2. Determine the optimal threshold for ΔSUVmax (delayed minus standard SUVmax);\n   3. Validate the sensitivity, specificity, and AUC of these thresholds in an independent validation set.\n2. Biopsy avoidance potential In patients with PI RADS 4-5 lesions, calculate the negative predictive value (NPV) using a predefined high threshold to estimate the proportion who could safely avoid biopsy.\n3. Diagnostic performance in key subgroups Compare the AUC of delayed SUVmax versus standard SUVmax for csPCa detection in patients with PI RADS 2-3 and in those with PI RADS 4-5.\n4. Additional lesion detection Proportion of patients with additional csPCa lesions detected only on delayed imaging, and the proportion whose PI RADS category would be upgraded based on these findings.\n5. Clinical decision impact Proportion of patients in whom management recommendations would change after incorporating delayed imaging results, compared with standard imaging alone.\n6. Exploratory subgroup analyses Stratify by PSA level (\\\u003C4, 4 10, \\>10 ng\u002FmL) and PSA density (\\\u003C0.10, 0.10-0.20, \\>0.20 ng\u002FmL\u002Fcc) to identify subgroups that derive the greatest benefit from delayed imaging; additionally, explore combined subgroups such as PI RADS 3 with PSA 4-10 or PSAD 0.10-0.20.\n\nInclusion Criteria\n\n1. Suspected prostate cancer based on elevated PSA (≥4.0 ng\u002FmL) or clinical symptoms\n2. Undergo PSMA PET (standard + delayed) prior to prostate biopsy\n3. Willing to undergo prostate biopsy\n4. Provide written informed consent Exclusion Criteria\n\n1\\. Prior prostate cancer treatment before PSMA PET imaging 2. Other malignancy within past two years 3. Investigator-judged risk of serious complications interfering with study conduct",[24,25,26],"Treatment-naive Prostate Cancer","Suspected Prostate Cancer","Molecular Imaging",[28,29,30,31,32],"Prostate Cancer","PSMA PET","Delayed imaging","Diagnostic","Efficacy","RECRUITING","2026-04-08",{"date":36,"type":37},"2026-04-15","ACTUAL",{"date":39,"type":37},"2021-03-05",{"date":41,"type":20},"2028-03-05",{"name":43,"class":44},"Xijing Hospital","OTHER",9,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100615594","novel-humanized-ferritin-based-nir-fluorescent-probe-for-identifying-sentinel-lymph-node-metastasis-in-early-gastric-cancer-100615594","NCT07294638","Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer","A Humanized Ferritin-Based NIR Fluorescent Probe for Discrimination Between Benign and Malignant Sentinel Lymph Nodes in Early Gastric Cancer","Inclusion Criteria:\n\n* Pathologically or cytologically confirmed early gastric cancer eligible for radical resection, with histologically verified adenocarcinoma component (cT1-cT2, tumor diameter ≤4 cm);Age≥18years；No gender restriction；voluntary participation with written informed consent.\n\nExclusion Criteria:\n\n* Patients deemed ineligible for participation by the investigator's assessment.","ALL",{"count":55,"type":20},47,"With the widespread adoption of early cancer screening, the proportion of early gastric cancer (EGC) in China has been gradually increasing. The primary treatments for EGC are endoscopic and surgical interventions. For EGC invading the submucosal layer, the lymph node metastasis rate is approximately 20%. In clinical practice, subtotal gastrectomy combined with D2 lymphadenectomy is commonly performed to achieve radical tumor resection, resulting in up to 80% of patients undergoing unnecessary lymph node dissection. Sentinel lymph nodes (SLNs), which are the first potential sites along the lymphatic drainage pathway from the primary tumor to receive cancer cells, can effectively represent the status of lymphatic metastasis. As gastric cancer surgery evolves toward minimally invasive, precise, and individualized approaches, there is an urgent clinical need for a safe and effective SLN mapping technique to intraoperatively distinguish between benign and malignant SLNs, thereby avoiding unnecessary lymphadenectomy and improving patient prognosis.\n\nCurrently, indocyanine green (ICG) is the only clinically approved near-infrared (NIR) fluorescent dye and is relatively widely used. However, it lacks targeting specificity, diffuses too rapidly, and has difficulty identifying micrometastases in SLNs. Therefore, we aimed to enhance ICG's targeting ability toward metastatic tumor cells to increase fluorescence signal intensity in malignant SLNs, enabling intraoperative differentiation between benign and malignant SLNs and reducing unnecessary lymph node dissection. Considering the high heterogeneity of tumor cells and the molecular diversity among metastatic foci within malignant SLNs, our team innovatively proposed a multi-target probe design to improve targeting capability against heterogeneous tumor cells. Based on molecular imaging technology combined with near-infrared (NIR) imaging, we developed a humanized ferritin-based probe (VE\u002FCX-FTn) targeting metastatic lymph nodes. Previous studies have confirmed the effective identification of metastatic lymph nodes by the VE\u002FCX-FTn probe.\n\nTo further validate the effectiveness of this probe in identifying SLN metastasis in early gastric cancer with a low lymph node metastasis rate, this study plans to use residual early gastric cancer tissues obtained from post-surgical resections to evaluate the probe's imaging capability for SLNs. Furthermore, a prospective clinical sample cohort study will be conducted to verify its diagnostic efficacy for metastatic lymph nodes of varying sizes. The aim is to demonstrate that our developed probe can guide the identification of SLNs in early gastric cancer and assist in determining the presence of SLN metastasis, thereby reducing unnecessary lymphadenectomy and improving patient prognosis.\n\nThis study employs a novel NIR fluorescent molecular probe, VE\u002FCX-FTn-ICG, based on humanized ferritin, with the objective of investigating its effectiveness in distinguishing between benign and malignant sentinel lymph nodes in early gastric cancer. Using this probe, we have already demonstrated that VE\u002FCX-FTn-ICG enables precise differentiation between benign and malignant lymph nodes in animal models. The probe specifically binds to tumor cells, exhibiting high targeting specificity and imaging capability, thereby providing real-time and accurate intraoperative imaging of SLNs for early gastric cancer surgery. A further goal of this study is to validate the application efficacy of this targeted probe in distinguishing between benign and malignant SLNs using ex vivo human early gastric cancer tissue samples. This aims to provide a reliable auxiliary tool for intraoperative SLN biopsy in early gastric cancer, assisting in avoiding unnecessary lymph node resection for patients, and ultimately improving surgical outcomes and patient prognosis.",[58,26],"Gastric Cancer","2025-12-08",{"date":61,"type":37},"2025-12-19",{"date":63,"type":37},"2025-07-15",{"date":65,"type":20},"2026-07-07",{"name":67,"class":44},"Nanfang Hospital, Southern Medical University",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":68},"100614227","novel-humanized-ferritin-based-nir-fluorescent-molecular-probe-for-identifying-tumor-margins-in-gastric-tissue-100614227","NCT07276854","Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue","Study of a Novel Near-Infrared (NIR) Fluorescent Molecular Probe Based on Humanized Ferritin for the Identification of Benign and Malignant Margins in Gastric Tissue","Inclusion Criteria:\n\n* Pathologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma eligible for radical resection, with histologically verified predominant adenocarcinoma component; Age ≥ 18 years; No gender restriction ; Voluntary participation with written informed consent.\n\nExclusion Criteria:\n\n* Patients who have received neoadjuvant therapy; Patients deemed ineligible for participation by the investigator's assessment.",{"count":77,"type":20},32,"Radical surgery remains the primary treatment for gastric cancer, but intraoperative tumor margin assessment relies on surgeons' visual inspection, limiting accuracy. There is thus an urgent clinical need for real-time visualisation of tumour margins.\n\nIn recent years, near-infrared (NIR) fluorescence imaging has emerged as a critical tool for precision tumor resection. However, existing probes like indocyanine green (ICG) lack tumor-targeting specificity. Ferritin (FTn), with its unique nanocage structure, excellent biosafety, and well-defined in vivo behavior, presents an attractive platform for targeted molecular probes.\n\nYet, translational challenges persist, including animal model limitations and clinical validation bottlenecks. To address this, our study employs freshly resected human gastric tissue in an ex vivo perfusion system, simulating the circulatory dynamics of the humanized ferritin-based probe FTn-ICG in vivo. Using a prospective clinical sample cohort, we aim to validate its diagnostic efficacy in delineating gastric cancer margins, ultimately overcoming the critical barrier of precise tumor boundary identification.",[58,26],"NOT_YET_RECRUITING","2025-11-30",{"date":83,"type":37},"2025-12-11",{"date":85,"type":20},"2025-12-30",{"date":87,"type":20},"2026-08-01",{"name":67,"class":44},{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":96,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":68},"100579906","her2-pet-as-a-precision-imaging-tool-for-treatment-with-her2-adc-in-her2-expressing-mbc-100579906","NCT06830382","HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC","A Multicentre, Prospective, Open-label Study With [68Ga]Ga-ABY-025 PET-imaging to Characterize HER2-expression and Explore the Therapy-predictive Value for HER2-antibody Drug Conjugates in Patients With Metastatic Breast Cancer","Inclusion Criteria:\n\n* Female patients age ≥18 years.\n* Metastatic or locally advanced breast cancer with disease progression after ≥ 1 line of chemotherapy in the palliative setting, or with disease relapse within six months after completion of (neo-) adjuvant chemotherapy.\n* The patient must be able and willing to provide written consent to participate in the study.\n* At least one metastatic lesion ≥ 10 mm is available for biopsy\n\n  o Exception can be made when a recent biopsy is available (no more than 12 months old and without exposition to HER2-targeted therapy or local radiotherapy to the specific lesion).\n* At least one additional metastatic index lesion ≥ 10 mm for evaluation of treatment effect (according to RECIST v1.1)\n* WHO performance status ≤ 2.\n* Expected survival \\> 12 weeks.\n* Contraceptives: Females of child-bearing potential must agree to use adequate contraception prior to study entry, for the duration of the study treatment phase and for six months after the last dose of \\[68Ga\\]Ga-ABY-025. Examples of contraceptive methods with a failure rate of \\\u003C 1% per year include bilateral tubal ligation, male sterilization, established, proper use of hormonal contraceptives that inhibit ovulation, hormone- releasing intrauterine devices (IUDs), and copper IUDs. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Women must refrain from donating eggs during this same period. Should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. If a female participant is of child-bearing potential (females are considered not of childbearing potential if they are at least one year postmenopausal and\u002For surgically sterile), she must have a documented negative serum Pregnancy testing prior to each administration of the IMP is obligatory.\n\nExclusion Criteria:\n\n* Contra-indications for treatment for trastuzumab deruxtecan and inability to undergo this treatment as per local treatment routines.\n* A previously documented metastatic tumor biopsy that was HER2-positive (IHC 3+ and\u002For HER2 gene amplification).\n* Other manifest malignancies except for basal cell carcinoma of the skin.\n* Inadequate cardiac, renal, bone marrow or liver function\n* Patients with increased risk of complications from biopsies, i.e. increased risk of bleeding, defined as\n\n  * prothrombin time test (INR value) \\>1.4, platelet count \\\u003C70 (109\u002Fl), activated partial thromboplastin time (APTT) \\>30s.\n  * known bleeding disorders such as haemophilia, von Willebrand disease or platelet disorders.\n  * any anticoagulants or antiplatelet treatment that cannot be temporarily paused","FEMALE",{"count":98,"type":20},70,"This is a prospective, multi-center, open-label, exploratory diagnostic phase II imaging trial for patients with metastatic breast cancer with at least one line of systemic therapy.\n\nThe overarching aim of the HER2-Ex PET trial is to study the role of precision imaging utilizing positron emission tomography (PET) with the HER2-specific tracer \\[68Ga\\]Ga-ABY-025 (hereafter referred to as HER2-PET) in enhancing treatment planning for patients with metastatic HER2-expressing breast cancer Patients will be allocated based on HER2-status on PET and biopsy. Patients with HER2-expressing lesions in a fresh or archived tumour biopsy will be treated with T-DXd.\n\nThe study hypothesis is that PET\u002FCT precision imaging with a contemporary HER2-radiotracer (\\[68Ga\\]Ga-ABY-025) can be used and can lead to a potentially better identification of patients who benefit from T-DXd treatment, thereby achieving improved treatment responses as well as fewer side effects. This study's diagnostic approach provides a more individualized treatment strategy. Additionally, this study can potentially give us a better biological understanding of HER2-expressing mBC.",[101,102,26],"Breast Cancer Stage IV","HER2-low Breast Cancer",[104,105,106,107,108,109,110],"HER2-PET","molecular imaging","precision imaging","HER2-low mBC","metastatic breast cancer","HER2-ADC","ABY-025","2025-11-17",{"date":113,"type":37},"2025-11-20",{"date":115,"type":37},"2025-10-03",{"date":117,"type":20},"2032-04-01",{"name":119,"class":44},"Renske Altena",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":96,"minAge":128,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":140,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":68},"100601760","molecular-breast-imaging-mbi-guided-biopsy-100601760","NCT07114679","Molecular Breast Imaging (MBI)-Guided Biopsy","Molecular Breast Imaging (MBI)-Guided Biopsy Pilot SBIR","MBI-GB-Pilot","Inclusion Criteria:\n\n* dense breasts (BI-RADS C or D) on screening DBT\n\nExclusion Criteria:\n\n* pregnancy","21 Years",{"count":130,"type":20},250,"INTERVENTIONAL",[133],"NA","The goal of this pilot clinical trial is to demonstrate supplemental screening MBI (molecular breast imaging) in women with dense breasts. The main questions it aims to answer are:\n\n* Does screening MBI find more cancer than screening DBT (3D mammography, digital breast tomosynthesis?\n* Does screening MBI result in more call-backs for biopsy than DBT?\n* How well does MBI-guided biopsy conform with pathology reports?\n\nResearchers will compare screening MBI to screening DBT to see if MBI is more sensitive to detecting cancer in women with dense breasts.\n\nParticipants will\n\n* Receive both screening DBT and screening MBI\n* Receive either DBT-guided or MBI-guided biopsy (randomly assigned), if required by the screening images",[136,137,26,138,139],"Breast Cancer Detection","Breast Neoplasm","Biopsy","Dense Breasts",[141,142,143,144,145,146,147,148,105],"screening","crossover","single-group","pilot","biopsy","randomized assignment","dense breasts","MBI","2025-08-03",{"date":151,"type":37},"2025-08-11",{"date":153,"type":20},"2027-06",{"date":155,"type":20},"2028-06",{"name":157,"class":158},"Smart Breast Corp.","INDUSTRY",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":131,"phases":168,"briefSummary":169,"conditions":170,"keywords":175,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":68},"100586103","68ga-fapi-46-in-staging-of-pancreatic-adenocarcinoma-100586103","NCT06911021","68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma","68Ga-FAPI-46 PET\u002FCT for Tumor Fibroblast Imaging to Refine Tumor Assessment and Therapeutic Strategies of Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Age ≥18 years.\n* Karnofsky index ≥80%.\n* Operable or operable borderline tumor after neoadjuvant chemotherapy response\n* Planned surgical tumor resection.\n* SOC imaging (ceCT and MRI) performed as pre-surgery exams.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Claustrophobia.\n* Severe renal insufficiency (GFR\\\u003C30 mL\u002Fmin\u002F1.73m²).\n* Liver enzymes (ALAT, ASAT \\>5× the upper limit).\n* Bilirubin \\>3× the upper limit.\n* Hemoglobin \\\u003C8 g\u002FdL.\n* Absolute neutrophil count \\\u003C1000\u002Fmm³.\n* Platelets \\\u003C75,000\u002FµL.\n* Inability to give informed consent or follow study procedures.\n* The patient refuses to receive information regarding incidental findings.",{"count":167,"type":20},20,[133],"This clinical study investigates the use of a new imaging technique called 68Ga-FAPI-46 PET\u002FCT in people with pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its rapid progression, late diagnosis, and poor survival rate. One of the main challenges with pancreatic cancer is that standard images like MRI and CT, while helpful, are not always able to clearly show how far the cancer has spread or where exactly the tumor ends. This can make surgery and treatment planning more difficult and less precise.\n\nThe new image technique being studied, 68Ga-FAPI-46 PET\u002FCT, works by injecting a small and safe amount of a radioactive substance into a vein. This substance travels through the body and attaches to a specific protein called FAP, which is found in large amounts in the tissue that surrounds many pancreatic tumors. By sticking to this protein, the tracer highlights not only the tumor but also the surrounding area that may be affected by the cancer. This results in very detailed images that may show the tumor more clearly than other techniques.\n\nEach participant in the study will receive a single injection of the tracer, and about an hour later they will have the PET\u002FCT scan. The scan itself is quick, painless, and non-invasive, and takes about 20 minutes. A few days later, participants will receive a follow-up phone call to check if they experienced any side effects, though previous studies with over 1,000 people have shown the tracer to be very safe.\n\nThe purpose of the study is to find out whether this new technique provides more useful and accurate information than the standard images currently used. It may help better detect the size of the tumor, see if it has spread to other parts of the body, and give doctors a clearer idea of how to plan surgery. This could make it easier to remove the tumor completely and choose the most effective treatment for each patient.\n\nThis pilot study is being conducted at Lausanne University Hospital (CHUV) with 20 adult participants over two years. CHUV is the first hospital in Switzerland to offer this kind of scan. If the study is successful, this scan may become a regular part of care for people with pancreatic cancer and could also be used in other cancers in the future.",[171,172,173,174,26],"Pancreatic Adenocarcinoma","PET \u002F CT","FAPI","Surgical Oncology",[176,177,178,179,180],"Novel imaging in pancreatic cancer","Fibroblast activation protein imaging","Cancer-associated fibroblasts","PET\u002FCT and pancreatic tumor","Tumor microenvironment imaging","2025-03-28",{"date":183,"type":37},"2025-04-04",{"date":185,"type":20},"2025-05-01",{"date":187,"type":20},"2027-12-31",{"name":189,"class":44},"Centre Hospitalier Universitaire Vaudois"]